FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications

FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications — Live Feedhttps://www.live-feeds.com/feed/fda-warns-of-rare-eye-condition-causing-blindness-from-glp-1-weight-loss-medicationsContinuously updated, source-cited coverage. FDA orders NAION blindness warnings on GLP-1 labelshttps://www.live-feeds.com/feed/fda-warns-of-rare-eye-condition-causing-blindness-from-glp-1-weight-loss-medicationshttps://www.live-feeds.com/feed/fda-warns-of-rare-eye-condition-causing-blindness-from-glp-1-weight-loss-medications#u202152Sun, 15 Nov 2026 09:45:59 +0000The U.S. Food and Drug Administration has ordered makers of GLP-1 drugs, including Ozempic, Wegovy, Zepbound and Mounjaro, to add label warnings about nonarteritic anterior ischemic optic neuropathy, a rare condition linked to sudden vision loss and potential permanent blindness. The agency acted after reviewing reports connecting the popular diabetes and weight-loss medications to the optic nerve disorder. No specific case counts were provided in the available material. Patients should consult doctors before stopping treatment.Why it mattersGLP-1 medications are widely prescribed for type 2 d